Related Experiment Video
Updated: Dec 19, 2025
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
Hongye Hu1, Buran Chen2, Danni Zheng2
1Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background:
Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer. An increasing number of studies have focused on the development of highly selective inhibitors that target PARP-1 over PARP-2, its closest isoform, to mitigate potential side effects. However, due to the highly conserved and similar binding sites of PARP-1 and PARP-2, there is a huge challenge for the discovery and design of PARP-1 inhibitors. Recently, it was reported that a potent PARP-1 inhibitor named NMS-P118 exhibited greater selectivity to PARP-1 over PARP-2 compared with a previously reported drug (Niraparib). However, the mechanisms underlying the effect of this inhibitor remains unclear.
Methods:
In the present study, classical molecular dynamics (MD) simulations and accelerated molecular dynamics (aMD) simulations combined with structural and energetic analysis were used to investigate the structural dynamics and selective mechanisms of PARP-1 and PARP-2 that are bound to NMS-P118 and Niraparib with distinct selectivity.
Results:
The results from classical MD simulations indicated that the selectivity of inhibitors may be controlled by electrostatic interactions, which were mainly due to the residues of Gln-322, Ser-328, Glu-335, and Tyr-455 in helix αF. The energetic differences were corroborated by the results from aMD simulations.
Conclusion:
This study provides new insights about how inhibitors specifically bind to PARP-1 over PARP-2, which may help facilitate the design of highly selective PARP-1 inhibitors in the future.
Insights
Developing selective Poly-ADP-ribose polymerases 1 (PARP-1) inhibitors for breast cancer is challenging. This study reveals that electrostatic interactions involving specific residues in PARP-1 are key to the selectivity of NMS-P118 over PARP-2.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Poly-ADP-ribose polymerases 1 (PARP-1) is a key therapeutic target for breast cancer treatment.
- Developing PARP-1 inhibitors with high selectivity over PARP-2 is crucial to minimize side effects due to their similar binding sites.
- NMS-P118 shows greater PARP-1 selectivity than Niraparib, but its inhibitory mechanisms require elucidation.
Purpose of the Study:
- To investigate the structural dynamics and selective binding mechanisms of PARP-1 and PARP-2 when bound to NMS-P118 and Niraparib.
- To understand the molecular basis for the distinct selectivity profiles of NMS-P118 and Niraparib.
Main Methods:
- Classical molecular dynamics (MD) simulations were employed to analyze the behavior of PARP-1 and PARP-2 with inhibitors.
- Accelerated molecular dynamics (aMD) simulations were used to further explore structural dynamics and energetic differences.
- Structural and energetic analyses were performed to identify key interactions driving inhibitor selectivity.
Main Results:
- Classical MD simulations identified electrostatic interactions involving Gln-322, Ser-328, Glu-335, and Tyr-455 in helix αF as critical for inhibitor selectivity.
- These electrostatic interactions primarily contribute to the differential binding of inhibitors to PARP-1 versus PARP-2.
- aMD simulations corroborated the energetic differences observed, supporting the role of electrostatic forces in selectivity.
Conclusions:
- The study elucidates the molecular mechanisms underlying the selective inhibition of PARP-1 over PARP-2 by NMS-P118.
- These findings provide valuable insights for the rational design of next-generation, highly selective PARP-1 inhibitors.
- This research may facilitate the development of more effective breast cancer therapies with reduced off-target effects.
More Related Videos
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
10:12Author Spotlight: Quantitative Detection of DNA Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
Related Concept Videos
01:02Long-patch Base Excision Repair
02:04Protein-protein Interfaces